Collaborative Registry to Determine the Natural History of Barth Syndrome
The purpose of this research study is to collect data that we hope will help answer those questions and improve outcomes for children with Barth Syndrome. We would like to create an active registry that composes details about Barth Syndrome so we can better understand the illness. As part of the registry, we would like to use a heart monitor to observe for abnormal heart rhythms and possible correlate with other clinical information.
Colon Cancer Screening & Prevention Program | NYU Langone Health
NYU Langone gastroenterologists specialize in colonoscopy screening for the prevention and early detection of colon cancer.
Colon Cancer Screening & Prevention Program Doctors | NYU Langone Health
Find a doctor at the Colon Cancer Screening & Prevention Program at NYU Langone.
Colorectal Cancer | NYU Langone Health
Specialists at NYU Langone’s Perlmutter Cancer Center offer prevention, screening, and personalized treatment plans for colorectal cancer.
Colorectal Cancer Screening | NYU Langone Health
NYU Langone specialists use colonoscopy and other screening techniques to help prevent and detect colorectal cancer.
Colorectal Cancer Screening Services | NYU Langone Health
At NYU Langone’s Perlmutter Cancer Center, we offer screening and prevention programs for colorectal cancer.
Combined Craniomaxillofacial and Upper Extremity Allotransplantation
The purpose of this study is to evaluate functional and aesthetic outcomes of combined facial and upper extremity composite tissue allografts on patients who have not achieved functional and aesthetic outcomes with conventional reconstructive surgical strategies and prosthetic devices.
ComboMATCH Treatment Trial E5: A Randomized Phase II Study of AMG 510 (Sotorasib) with or without Panitumumab in Advanced Solid Tumors
This study will have two groups of patients to test the combination of AMG 510 (Sotorasib) and panitumumab for advanced cancers with KRAS G12C mutations. Group 1 is a randomized phase II trial for patients with advanced solid tumors (except lung and colorectal cancer) who haven’t had treatment with a KRAS G12C inhibitor before. Patients will be randomly assigned to either AMG 510 alone or AMG 510 combined with panitumumab, with AMG 510 given at 960 mg once a day and panitumumab at 6 mg/kg every two weeks. Group 2 is for patients who have already used a KRAS G12C inhibitor and had their cancer progress. Patients in this group can have any type of tumor, including lung or colon cancer. Treatment will continue until the cancer grows or the side effects become too severe, and tumors will be checked every 8 weeks. The main goal of the study is to measure how well the treatment works by looking at the response rate.
Common Neurological Tests | NYU Langone Health
Neurological exams help the neurosurgeons at NYU Langone pinpoint the cause of your condition and develop effective treatment strategies.
Common Questions | NYU Langone Health
Find answers to common questions about Virtual Urgent Care offered by an NYU Langone provider.